Related Experiment Video
Updated: Jun 16, 2026
04:29
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Therapeutic options for treatment-resistant depression
Richard C Shelton1, Olawale Osuntokun, Alexandra N Heinloth
1Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
CNS Drugs
|January 22, 2010
Summary
Treatment-resistant depression (TRD) has limited treatment options and poor outcomes, despite various pharmacological and non-pharmacological strategies. Further research is crucial for better clinical guidance and improved patient prognosis in TRD.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Treatment-resistant depression (TRD) poses significant challenges due to a lack of universal definition and decreasing remission chances after two failed treatment trials.
- Optimized therapies often fail in TRD, necessitating consideration of various pharmacological and non-pharmacological interventions.
Purpose of the Study:
- To review current pharmacological and non-pharmacological treatment strategies for treatment-resistant depression (TRD).
- To highlight the challenges and unmet medical needs in managing TRD.
- To emphasize the need for further research to guide clinical decision-making in TRD.
Main Methods:
- Review of non-pharmacological strategies: psychotherapy, electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial stimulation, deep brain stimulation, and psychosurgery.
- Categorization of pharmacological treatments into 'switching' (within/between drug classes) and 'combining' (with antidepressants or augmenting agents).
- Exploration of experimental pharmaceutical alternatives and their combination therapies for TRD.
Main Results:
- Non-pharmacological options like vagus nerve stimulation show benefits after prolonged use, while others remain experimental.
- Switching strategies offer advantages like avoiding polypharmacy but risk losing partial treatment responses.
- Combination strategies can build on improvements but involve multiple medications and increased adverse events; atypical antipsychotics (e.g., olanzapine/fluoxetine, aripiprazole) are increasingly used.
Conclusions:
- TRD remains poorly defined with limited approved agents (aripiprazole, olanzapine/fluoxetine) and generally poor outcomes.
- The heterogeneity of depression suggests diverse underlying pathologies, requiring individualized treatment evaluation for unresponsive patients.
- Continued research is essential to improve treatment guidance, as prolonged unsuccessful treatment correlates with worse long-term prognosis.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...